Patient Experience Data: Get Your Copy at DIA
Newly released book edited by Matt Reaney, (PhD, CPsychol, CSci, MSc), head, science and analytics, PCS, at IQVIA focuses on patient experience data with all levels of clinical research in mind.
IQVIA’s Patient Centered Solutions (PCS) team is distributing print copies of a newly released book, Using Patient Experience Data to Evaluate Medical Interventions. Generating, Understanding and Using Patient Experience Data Within and Alongside Clinical Trials, at the DIA meeting in Boston at the end of this month. If you are not on hand to pick up a complimentary copy, it will also be available for purchase at the Kindle store as an eBook.
Edited by Matt Reaney, (PhD, CPsychol, CSci, MSc), head, science and analytics, PCS, at IQVIA, the content is timely and the company believes it has the potential to become the authoritative text on patient-experience data (PED) in drug development. It was created with all levels and roles of clinical research in mind, with the intent to use the content to facilitate their work in bringing their products to the market.
Reaney outlines in Chapter 1, “Patient experience data (PED) in intervention development – what it is, why you should care, and how this book can help?” He writes, “The relevance of PED extends beyond patientlevel healthcare and into the development of new interventions. Indeed, understanding PED in intervention development is an important precursor to patient-focused healthcare provision. The goal of intervention development has long been to maximize health and well-being, but it is only recently that developers and sponsors of intervention development have recognized the importance of the patient experience in achieving this goal.”
- He continues to outline the reasons why PED could be considered confusing, why it is becoming more important and how it can be used effectively. For example, PED can help answer the following questions:
- What signs and symptoms are most bothersome to patients?
- How are patients' lives affected by disease and treatment?
- How can we best understand treatment benefit?
- Do patient preferences align with clinical priorities?
- How well do typical trial endpoints align with outcomes that matter most to patients?
- How do attitudes toward interventions vary by patient subgroup?
The book is broken down into four important sections of PED—generating, understanding, using, and developing a PED strategy. IQVIA contributing authors range the professional functions within the organization from PCS, to statistics, research, endpoints, and many more to reflect their expertise to the included sections.
Lisa Henderson, editor-in-chief, Applied Clinical Trials
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials
July 31st 2025In this pilot episode of the Applied Clinical Trials Brief, we examine the renewed push for placebo-controlled vaccine trials in the US, why experts warn it violates core ethical standards, and how these proposals could jeopardize both participant safety and future innovation.
Cardiff Reports 49% Response Rate With Onvansertib in RAS-Mutated Colorectal Cancer
July 31st 2025In the ongoing Phase II CRDF-004 trial, onvansertib plus standard-of-care showed a 49% confirmed ORR and early PFS benefit in first-line RAS-mutated metastatic colorectal cancer, with a favorable safety profile and dose-dependent efficacy across endpoints.
Unifying Industry to Better Understand GCP Guidance
July 31st 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
